- Home
- KZR vs RLYB Comparison
KZR vs RLYB Comparison
Compare KZR & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZR
- RLYB
- Stock Information
- Founded
- KZR 2015
- RLYB 2018
- Country
- KZR United States
- RLYB United States
- Employees
- KZR N/A
- RLYB N/A
- Industry
- KZR Biotechnology: Pharmaceutical Preparations
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- KZR Health Care
- RLYB Health Care
- Exchange
- KZR Nasdaq
- RLYB Nasdaq
- Market Cap
- KZR 46.5M
- RLYB 42.7M
- IPO Year
- KZR 2018
- RLYB 2021
- Fundamental
- Price
- KZR $6.19
- RLYB $0.88
- Analyst Decision
- KZR Hold
- RLYB Buy
- Analyst Count
- KZR 2
- RLYB 6
- Target Price
- KZR $9.00
- RLYB $8.10
- AVG Volume (30 Days)
- KZR 48.3K
- RLYB 94.1K
- Earning Date
- KZR 03-13-2025
- RLYB 03-11-2025
- Dividend Yield
- KZR N/A
- RLYB N/A
- EPS Growth
- KZR N/A
- RLYB N/A
- EPS
- KZR N/A
- RLYB N/A
- Revenue
- KZR N/A
- RLYB $598,000.00
- Revenue This Year
- KZR N/A
- RLYB N/A
- Revenue Next Year
- KZR N/A
- RLYB N/A
- P/E Ratio
- KZR N/A
- RLYB N/A
- Revenue Growth
- KZR N/A
- RLYB N/A
- 52 Week Low
- KZR $5.20
- RLYB $0.84
- 52 Week High
- KZR $11.40
- RLYB $3.46
- Technical
- Relative Strength Index (RSI)
- KZR 38.28
- RLYB 37.61
- Support Level
- KZR $6.15
- RLYB $0.89
- Resistance Level
- KZR $6.50
- RLYB $0.95
- Average True Range (ATR)
- KZR 0.29
- RLYB 0.07
- MACD
- KZR -0.02
- RLYB -0.01
- Stochastic Oscillator
- KZR 5.13
- RLYB 4.74
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.